Drugs / SAR445877
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07500298 | May 2026 → Dec 2030 expected | colorectal cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05584670 | Nov 2022 → Jan 2027 expected | cancer | Sanofi | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07692204 | Jul 2026 → Aug 2028 expected | carcinoma of esophagus, gastric cancer | Sanofi | Recruiting | No outcome recorded |
| Phase 2 | NCT07133425 | Nov 2025 → Feb 2028 expected | non-small cell lung carcinoma, refractory malignant neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR445877 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07500298 ↗ |
| Route | Intravenous | “SAR445877 monotherapy will be administered intravenously” NCT05584670 ↗ |